AI-powered search
Try Polaris, our new AI-powered search!

How does ruxolitinib compare with topical calcineurin inhibitors and topical steroids?

Featuring Alexandra Golant, MD |

Medical Director, Dermatology Faculty Practice
Associate Director, Residency Program
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

| Published January 31, 2022

More from this series

Who is a good candidate for lebrikizumab?

Atopic Dermatitis

Who is a good candidate for lebrikizumab?

Featuring Raj Chovatiya, MD, PhD, MSCI

What is the dosing regimen for lebrikizumab?

Atopic Dermatitis

What is the dosing regimen for lebrikizumab?

Featuring Raj Chovatiya, MD, PhD, MSCI

What is the safety profile of lebrikizumab?

Atopic Dermatitis

What is the safety profile of lebrikizumab?

Featuring Raj Chovatiya, MD, PhD, MSCI